Gentian Diagnostics AS (OSTO:GENTOO) Shares Outstanding (EOP): 15.5 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:GENTOO Gentian Diagnostics AS OSTO:GENTOO
60 GF Score
Price kr40.00
GF Value kr53.59
Valuation Modestly Undervalued
View Full Analysis

What is Gentian Diagnostics AS Shares Outstanding (EOP)?

Gentian Diagnostics AS OSTO:GENTOO 60 Shares Outstanding (EOP) is 15.5 Mil as of Jun. 2026. GuruFocus rates OSTO:GENTOO with a GF Score™ of 60/100 and a GF Value™ of kr53.59 (Modestly Undervalued).

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Gentian Diagnostics AS's shares outstanding for the quarter that ended in Jun. 2026 was 15.5 Mil.

Gentian Diagnostics AS's quarterly shares outstanding stayed the same from Mar. 2026 (15.5 Mil) to Jun. 2026 (15.5 Mil).

Gentian Diagnostics AS's annual shares outstanding stayed the same from Dec. 2024 (15.4 Mil) to Dec. 2025 (15.4 Mil).


Gentian Diagnostics AS  (OSTO:GENTOo) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Gentian Diagnostics AS Shares Outstanding (EOP) Related Terms


Gentian Diagnostics AS Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Gentian Diagnostics AS's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gentian Diagnostics AS Shares Outstanding (EOP) Chart

Gentian Diagnostics AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.42 15.42 15.42 15.42 15.42

Gentian Diagnostics AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.42 15.42 15.42 15.46 15.46

OSTO:GENTOO vs ABT, SYK, MDT: Shares Outstanding (EOP) Comparison

For the Medical Devices subindustry, Gentian Diagnostics AS's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gentian Diagnostics AS Shares Outstanding (EOP) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Gentian Diagnostics AS's Shares Outstanding (EOP) falls into.


OSTO:GENTOO
60GF Score
Gentian Diagnostics AS OSTO:GENTOO
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gentian Diagnostics AS Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 15.5 Mil mean?
Gentian Diagnostics AS (OSTO:GENTOO) has a Shares Outstanding (EOP) of 15.5 Mil as of Jun. 2026. The total shares a company has outstanding, at period-end. View historical data on Gentian Diagnostics AS and its competitors.
Is Gentian Diagnostics AS's Shares Outstanding (EOP) too high?
Gentian Diagnostics AS's current Shares Outstanding (EOP) is 15.5 Mil. Overall, Gentian Diagnostics AS has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Shares Outstanding (EOP) compare to ABT and SYK?
Gentian Diagnostics AS's Shares Outstanding (EOP) of 15.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Devices & Instruments company?
A good Shares Outstanding (EOP) depends on the Medical Devices & Instruments industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current Shares Outstanding (EOP) is 15.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSTO:GENTOO) is currently considered Modestly Undervalued. The stock's GF Value™ is kr53.59, compared to a current price of kr40.00 — trading 25.4% below its estimated fair value. The current Shares Outstanding (EOP) is 15.5 Mil. Gentian Diagnostics AS's overall GF Score™ is 60/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Gentian Diagnostics AS (OSTO:GENTOO), the current Shares Outstanding (EOP) is 15.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gentian Diagnostics AS (OSTO:GENTOO) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of kr40.00 is trading 25.4% below its estimated GF Value™ of kr53.59. GuruFocus considers Gentian Diagnostics AS to be Modestly Undervalued.

Key valuation signals for OSTO:GENTOO:

  • Shares Outstanding (EOP): 15.5 Mil
  • GF Value™: kr53.59 vs. price of kr40.00 (25.4% below fair value)
  • GF Score™: 60/100

No single metric tells the full story. See the OSTO:GENTOO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gentian Diagnostics AS Business Description

Other Exchanges GENT:Norway6FK:Germany
Address Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
60GF Score

Get the complete analysis for OSTO:GENTOO

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr40.00
Price
kr53.59
GF Value